NASDAQ:CDXS - Nasdaq - US1920051067 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to CDXS. CDXS was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of CDXS have multiple concerns. CDXS is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -43.81% | ||
ROE | -97.53% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 72.55% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.43 | ||
Debt/FCF | N/A | ||
Altman-Z | -4.05 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.18 | ||
Quick Ratio | 4.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.52
+0.2 (+8.62%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.52 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.12 | ||
P/tB | 3.24 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -43.81% | ||
ROE | -97.53% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 72.55% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.43 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 87.04% | ||
Cap/Sales | 7.25% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.18 | ||
Quick Ratio | 4.1 | ||
Altman-Z | -4.05 |